OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+72%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$766M
AUM Growth
+$254M
(+50%)
Cap. Flow
+$40.1M
Cap. Flow
% of AUM
5.24%
Top 10 Holdings %
Top 10 Hldgs %
55.55%
Holding
68
New
13
Increased
17
Reduced
11
Closed
9
Top Buys
| 1 |
Ocular Therapeutix
OCUL
|
$10.9M |
| 2 |
Cytokinetics
CYTK
|
$7.77M |
| 3 |
FSDC
FS Development Corp. Class A Common Stock
FSDC
|
$7.75M |
| 4 |
Protagonist Therapeutics
PTGX
|
$7.02M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$6.76M |
Top Sells
| 1 |
ATXI
Avenue Therapeutics, Inc. Common Stock
ATXI
|
$10.7M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
$4.38M |
| 3 |
Fulcrum Therapeutics
FULC
|
$4.26M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$3.76M |
| 5 |
MacroGenics
MGNX
|
$3.58M |
Sector Composition
| 1 | Healthcare | 95.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
MacroGenics
MGNX
$119M
| $8.47M | 1.11% |
370,600
-156,400
| -30% | -$3.58M |
|
|
FSDC
27
DELISTED
FS Development Corp. Class A Common Stock
FSDC
| $7.75M | 1.01% |
+704,400
| New | +$7.75M |
|
|
28
Protagonist Therapeutics
PTGX
$3.6B
| $7.02M | 0.92% |
+260,000
| New | +$7.02M |
|
29
Sutro Biopharma
STRO
$82.2M
| $7M | 0.91% |
322,200
+176,200
| +121% | +$3.83M |
|
30
Avalo Therapeutics
AVTX
$141M
| $6.92M | 0.9% |
910
-261
| -22% | -$1.98M |
|
|
TCDA
31
DELISTED
Tricida, Inc. Common Stock
TCDA
| $6.76M | 0.88% |
+959,000
| New | +$6.76M |
|
|
INFI
32
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $6.72M | 0.88% |
3,171,800
| – | – |
|
|
FPRX
33
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $6.5M | 0.85% |
+381,900
| New | +$6.5M |
|
|
ADMS
34
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $6.44M | 0.84% |
1,487,800
| – | – |
|
35
Merus
MRUS
$5.07B
| $6.19M | 0.81% |
353,000
+352,800
| +176,400% | +$6.18M |
|
|
SIOX
36
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $5.56M | 0.73% |
2,000,000
-39,100
| -2% | -$109K |
|
37
TELA Bio
TELA
$64.6M
| $5.49M | 0.72% |
365,000
+2,926
| +0.8% | +$44K |
|
38
FibroGen
FGEN
$49.8M
| $5.45M | 0.71% |
5,880
| – | – |
|
39
Verastem
VSTM
$600M
| $4.76M | 0.62% |
193,750
+10,417
| +6% | +$256K |
|
40
MEI Pharma
MEIP
$148M
| $4.11M | 0.54% |
77,800
| – | – |
|
41
Kiniksa Pharmaceuticals
KNSA
$2.62B
| $3.96M | 0.52% |
224,100
-113,900
| -34% | -$2.01M |
|
42
Kezar Life Sciences
KZR
$28M
| $3.7M | 0.48% |
70,800
+3,000
| +4% | +$157K |
|
|
APTO
43
DELISTED
Aptose Biosciences, Inc.
APTO
| $3.5M | 0.46% |
1,778
-2,220
| -56% | -$4.38M |
|
44
Praxis Precision Medicines
PRAX
$971M
| $3.49M | 0.46% |
+4,228
| New | +$3.49M |
|
45
Rhythm Pharmaceuticals
RYTM
$6.84B
| $3.42M | 0.45% |
+115,000
| New | +$3.42M |
|
|
EDAP
46
EDAP TMS
EDAP
$92.7M
| $3.4M | 0.44% |
657,500
-382,500
| -37% | -$1.98M |
|
47
ESSA Pharma
EPIX
$11M
| $3.39M | 0.44% |
284,050
+12,700
| +5% | +$152K |
|
|
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $3.21M | 0.42% |
254,000
+154,000
| +154% | +$1.95M |
|
|
CFRX
49
DELISTED
ContraFect Corporation
CFRX
| $2.22M | 0.29% |
5,500
+2,673
| +95% | +$1.08M |
|
|
OPTN
50
DELISTED
OptiNose
OPTN
| $1.8M | 0.24% |
+29,000
| New | +$1.8M |
|